AstraZeneca shares rise
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.
Goldman Sachs updated its price target on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN) shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The adjustment follows a ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...
The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it ...
Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer: Cambridge, UK Tuesday, February 4, 2025, 09:00 Hrs [IST] Astr ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback